Showing 21-30 of 127 results for "".
- National Rosacea Society Awards Three New Grantshttps://practicaldermatology.com/news/national-rosacea-society-awards-three-new-grants/2458430/The National Rosacea Society (NRS) is funding three new studies in addition to continuing support for two ongoing studies as part of its research grants program. In this round, Luis Garza, MD, an associate professor of dermatology at Johns Hopkins University in Baltimore, and colleagues were award…
- Six Dermatology Biotechs Combine to Form Alys Pharmaceuticalshttps://practicaldermatology.com/news/six-dermatology-biotechs-combine-to-form-alys-pharmaceuticals/2462241/Originating from the aggregation of six asset-centric dermatology companies, Alys Pharmaceuticals was launched with $100 million financing by Medicxi, a healthcare-focused investment firm. Alys combines the assets and platforms of Aldena Therapeutics, Graegis Pharmaceuticals, Granular Therapeutic…
- Novartis Premieres New HS Docuseries at Tribeca Film Festivalhttps://practicaldermatology.com/news/novartis-premieres-new-hs-docuseries-at-tribeca-film-festival/2461768/Novartis is launching a new docuseries, "The Beacons: Illuminating HS Stories, in recognition of Hidradenitis Suppurativa (HS) Awareness Week. The series, which will premiere during the 2023 Tribeca Festival in New York, is part of the "Shine a Light on HS" campaign, which was developed by Novarti…
- Dong-A ST: Phase 3 Trial Shows Therapeutic Equivalence Between Plaque Psoriasis Drug Candidate DMB-3115 and Stelarahttps://practicaldermatology.com/news/dong-a-st-demonstrates-therapeutic-equivalence-between-plaque-psoriasis-drug-candidate-dmb-3115-and-stelara-in-phase-3-trial/2461504/South Korea-based Dong-A ST announced that therapeutic equivalence and safety were established between DMB-3115 and Stelara (ustekinumab; Janssen Biotech), the reference drug, in global phase 3 trials. Stelara is indicated for plaque psoriasis, psoriatic arthritis, Crohn’s disease, and ulcerative…
- Pulsed-Dye Laser Reduces the Effects of Hypertrophic Scars Post-thyroidectomyhttps://practicaldermatology.com/news/pulsed-dye-laser-reduces-the-effects-of-hypertrophic-scars-post-thyroidectomy/2461308/Treatment with a 595 nm pulsed dye laser (PDL) can prevent and improve hypertrophic scars in patients with post-thyroidectomy in a cost-effective fashion, a new study shows. For the study, 19 patients with hypertrophic scars after thyroidectomy underwent eight treatment sessions with the 595 nm PD…
- Safety and Tolerability Update for LEO's Tralokinumabhttps://practicaldermatology.com/news/safety-and-tolerability-update-for-leos-tralokinumab-1/2460590/LEO Pharma’s tralokinumab is well tolerated when used as monotherapy or in combination therapy with the topical corticosteroid (TCS) mometasone furoate, according to a late-breaking data analysis presented online at European Academy of Dermatology and Venereology (EADV) Virtual 2020. Tralokinumab i…
- FDA Fast Tracks Leo Pharma’s Delgocitinib Cream for Hand Eczemahttps://practicaldermatology.com/news/fda-fast-tracks-leo-pharmas-delgocitinib-cream-for-hand-eczema/2460490/Delgocitinib cream, Leo Pharma’s investigational topical pan-Janus kinase (JAK)-inhibitor, has been granted Fast Track designation by the U.S. Food and Drug Administration (FDA) for the potential treatment of adults with moderate-to-severe chronic hand eczema (CHE). There are currently no treatmen…
- LEO Pharma Enters License Agreement with Oneness Biotech, Microbio Shanghai for Atopic Dermatitis and Asthma Drug Candidatehttps://practicaldermatology.com/news/leo-pharma-enters-license-agreement-with-oneness-biotech-microbio-shanghai-for-atopic-dermatitis-and-asthma-drug-candidate/2460353/LEO Pharma A/S has signed a worldwide exclusive licensing agreement with Oneness Biotech of Taiwan and Microbio Shanghai of China, covering the development and commercialization of the novel Atopic Dermatitis (AD) and Allergic Asthma drug candidate, FB825. FB825 is a first-in-class drug candidate …
- LEO Pharma Focuses on Translational Medicine, Appoints Dr. Adam B. Raff as Director & Medical Advisorhttps://practicaldermatology.com/news/leo-pharma-strengthens-focus-on-translational-medicine-with-appointment-of-dr-adam-b-raff-as-director-medical-advisor/2459942/LEO Pharma has appointed Adam B. Raff, MD, PhD as Director and Medical Advisor in Translational Medicine, effective January 28. Dr. Raff’s primary objective will be to support LEO Pharma’s ambitions to advance science within dermatology through translational medicine, the company says. Adam Raff i…
- Is Widespread Vitamin D Deficiency Due to Chronic Disease, Sunscreen Use? New Study Says Yeshttps://practicaldermatology.com/news/is-widespread-vitamin-d-deficiency-due-to-chronic-disease-sunscreen-use-new-study-says-yes/2458205/Nearly 1 billion people worldwide may have deficient or insufficient levels of vitamin D due to chronic disease and inadequate sun exposure related to sunscreen use, according to a study in the Journal of the American Osteopathic Association. The study also found that 95 percent of African America…